Muscle Spasticity - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Muscle Spasticity – Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Muscle Spasticity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Muscle Spasticity: Overview
Spasticity is a condition in which muscles stiffen or tighten, preventing normal fluid movement. The muscles remain contracted and resist being stretched, thus affecting movement, speech and gait. Spasticity is generally caused by damage or disruption to the area of the brain and spinal cord that are responsible for controlling muscle and stretch reflexes. These disruptions can be due to an imbalance in the inhibitory and excitatory signals sent to the muscles, causing them to lock in place. Spasticity can be harmful to growing children as it can affect muscles and joints. People with brain injury, spinal cord injury, cerebral palsy or multiple sclerosis can have varying degrees of spasticity. Symptoms of spasticity can vary from being mild stiffness or tightening of muscles to painful and uncontrollable spasms. Pain or tightness in joints is also common in spasticity. Due to the varying degrees of spasticity, diagnosis may not be so simple. A physical examination with neurological testing will be done to test for spasticity and the severity of it. Imaging such as magnetic resonance imaging (MRI) can provide more information on the source of spasticity and the extent of the damage that has caused it. Many medications are used to treat spasticity, including: botulinum toxin: injected directly into spastic muscles, baclofen: muscle relaxant, diazepam: sedative, phenol: nerve blocker, and tizanidine: calms spasms and relaxes tight muscles.
'Muscle Spasticity - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Muscle Spasticity pipeline landscape is provided which includes the disease overview and Muscle Spasticity treatment guidelines. The assessment part of the report embraces, in depth Muscle Spasticity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Muscle Spasticity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Muscle Spasticity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Muscle Spasticity Emerging Drugs
Further product details are provided in the report……..
Muscle Spasticity: Therapeutic Assessment
This segment of the report provides insights about the different Muscle Spasticity drugs segregated based on following parameters that define the scope of the report, such as:
Muscle Spasticity: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Muscle Spasticity therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Muscle Spasticity drugs.
Muscle Spasticity Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Muscle Spasticity – Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Muscle Spasticity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Muscle Spasticity: Overview
Spasticity is a condition in which muscles stiffen or tighten, preventing normal fluid movement. The muscles remain contracted and resist being stretched, thus affecting movement, speech and gait. Spasticity is generally caused by damage or disruption to the area of the brain and spinal cord that are responsible for controlling muscle and stretch reflexes. These disruptions can be due to an imbalance in the inhibitory and excitatory signals sent to the muscles, causing them to lock in place. Spasticity can be harmful to growing children as it can affect muscles and joints. People with brain injury, spinal cord injury, cerebral palsy or multiple sclerosis can have varying degrees of spasticity. Symptoms of spasticity can vary from being mild stiffness or tightening of muscles to painful and uncontrollable spasms. Pain or tightness in joints is also common in spasticity. Due to the varying degrees of spasticity, diagnosis may not be so simple. A physical examination with neurological testing will be done to test for spasticity and the severity of it. Imaging such as magnetic resonance imaging (MRI) can provide more information on the source of spasticity and the extent of the damage that has caused it. Many medications are used to treat spasticity, including: botulinum toxin: injected directly into spastic muscles, baclofen: muscle relaxant, diazepam: sedative, phenol: nerve blocker, and tizanidine: calms spasms and relaxes tight muscles.
'Muscle Spasticity - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Muscle Spasticity pipeline landscape is provided which includes the disease overview and Muscle Spasticity treatment guidelines. The assessment part of the report embraces, in depth Muscle Spasticity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Muscle Spasticity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Muscle Spasticity R&D. The therapies under development are focused on novel approaches to treat/improve Muscle Spasticity.
This segment of the Muscle Spasticity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Muscle Spasticity Emerging Drugs
- Arbaclofen ER: Osmotica Pharmaceuticals
Further product details are provided in the report……..
Muscle Spasticity: Therapeutic Assessment
This segment of the report provides insights about the different Muscle Spasticity drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Muscle Spasticity
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Muscle Spasticity: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Muscle Spasticity therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Muscle Spasticity drugs.
Muscle Spasticity Report Insights
- Muscle Spasticity Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Muscle Spasticity drugs?
- How many Muscle Spasticity drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Muscle Spasticity?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Muscle Spasticity therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Muscle Spasticity and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Muscle Spasticity: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Arbaclofen ER: Osmotica Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
MPH-220: Motor Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Muscle Spasticity Key Companies
Muscle Spasticity Key Products
Muscle Spasticity- Unmet Needs
Muscle Spasticity- Market Drivers and Barriers
Muscle Spasticity- Future Perspectives and Conclusion
Muscle Spasticity Analyst Views
Muscle Spasticity Key Companies
Appendix
Executive Summary
Muscle Spasticity: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Arbaclofen ER: Osmotica Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
MPH-220: Motor Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Muscle Spasticity Key Companies
Muscle Spasticity Key Products
Muscle Spasticity- Unmet Needs
Muscle Spasticity- Market Drivers and Barriers
Muscle Spasticity- Future Perspectives and Conclusion
Muscle Spasticity Analyst Views
Muscle Spasticity Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Muscle Spasticity
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Muscle Spasticity
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Muscle Spasticity
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Muscle Spasticity
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
